AHA, others file amicus briefs opposing major drug companies’ 340B rebate models
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject drug companies’ proposed 340B rebate models in separate lawsuits brought by a number of drug companies to bar the agency from doing so.
The AHA filed the following friend-of-the-court briefs:
- March 6 brief in case brought by Sanofi.
- March 5 brief in case brought by Kalderos.
- March 4 brief in case brought by Eli Lilly, Bristol Meyers Squibb and Novartis.
- Feb. 28 brief in case brought by Johnson & Johnson.
Others joining the AHA in the friend-of-the-court briefs were the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.
Related News Articles
Headline
The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program because “a rebate mechanism of any kind…
Headline
The AHA and others April 17 filed an amicus brief requesting the U.S. Court of Appeals for the 4th Circuit grant en banc review of a panel decision that…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The U.S. District Court for the District of Columbia March 31 vacated a Health Resources and Services Administration policy instituted in 2013 that restricted…
Headline
The U.S. Court of Appeals for the 4th Circuit March 31 upheld a preliminary injunction issued by the U.S. District Court for the District of West Virginia…
Headline
The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk policy from taking effect…